Nephrology and end-stage kidney disease
Pathalys Pharma Inc. focuses on clinical research in ESKD populations receiving maintenance hemodialysis, with attention to complications that arise in advanced kidney failure.
- Chronic hemodialysis populations
- Kidney failure-related complications
The sponsor’s active studies are centered on patients with advanced renal disease in dialysis settings across multiple collaborating sites.
Secondary hyperparathyroidism
Its clinical program is directed toward secondary hyperparathyroidism in individuals with kidney disease, reflecting interest in disorders of mineral and endocrine balance associated with renal impairment.
- Parathyroid hormone dysregulation
- Mineral metabolism disorders
Research activity in this area is aimed at patients with persistent SHPT during dialysis care.
Dialysis-related endocrine care
The sponsor’s trials examine treatment needs within the routine management of hemodialysis patients, where endocrine complications intersect with chronic renal replacement therapy.
- Dialysis patient management
- Renal osteodystrophy–related concerns
This therapeutic focus places emphasis on conditions that affect long-term care in the dialysis population.
Safety and long-term treatment tolerability
Clinical research also addresses the ongoing tolerability of therapies used for secondary hyperparathyroidism in people with advanced kidney disease.
- Long-term safety
- Chronic therapy monitoring
This area is relevant to sustained treatment use in a medically complex dialysis population.
